Hormone Receptor-positive Breast Cancer Clinical Trials in Boston, Massachusetts

5 studies are recruiting for hormone receptor-positive breast cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

   The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Kristina A. Fanucci

   See if you can join NCT07222215 on ClinicalTrials.gov

2. ETHAN - ET for Male BC

   This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemacicl…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   9 in total

   Run by

   Jose Pablo Leone

   See if you can join NCT05501704 on ClinicalTrials.gov

3. Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

   This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Oana Danciu

   See if you can join NCT05467891 on ClinicalTrials.gov

4. Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   Ellipses Pharma

   See if you can join NCT05573126 on ClinicalTrials.gov

5. VS-6766+Abema+Fulv in Met HR+/HER- BC

   This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Adrienne G. Waks

   See if you can join NCT05608252 on ClinicalTrials.gov